SI-BONE Inc

SIBN

Market cap $763M

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%

After reaching an important support level, SiBone (SIBN) could be a good stock pick from a technical perspective. SIBN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, December 2, 2025, at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time.

The medical device maker posted a satisfying beat-and-raise third quarter. During the period, it managed to narrow its net loss considerably.

SI-BONE, Inc. ( SIBN ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Saqib Iqbal - Director of FP&A and Investor Relations Laura Francis - CEO & Director Anshul Maheshwari - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Gracia Mahoney - BofA Securities, Research Division Young Li - Jefferies LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division David Saxon - Needham & Company, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.16 per share a year ago.

Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter

Ligand Pharmaceuticals (LGND) (Health Care, Pharmaceuticals) shares rose after announcing adjusted earnings per share that came in ahead of consensus. Acadian Asset Management (AAMI) (Financials, Asset Management & Custody Banks) saw another quarter of better-than-expected flows, driving earnings upside relative to expectations. SI-Bone (SIBN) (Health Care, Health Care Equipment) was weaker despite reporting a marginal beat on revenue and expectations of improved profitability.

SANTA CLARA, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2025 after market close on Monday, November 10, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NEWTOWN, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at SI-Bone, Inc. (“SI-Bone”).